Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MiMedx: Q3 Earnings Snapshot

11/02/2021 | 05:30pm EST

MARIETTA, Ga. (AP) _ MiMedx Group Inc. (MDXG) on Tuesday reported a loss of $2.3 million in its third quarter.

The Marietta, Georgia-based company said it had a loss of 4 cents per share.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 8 cents per share.

The developer of biomaterials made from sterilized human amniotic membrane posted revenue of $63.1 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $60.3 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MDXG at https://www.zacks.com/ap/MDXG

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about MIMEDX GROUP, INC.
01/10MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosu..
AQ
01/10MIMEDX Outlines Key Strategic Milestones for 2022
AQ
01/10MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022
CI
01/04MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
AQ
2021MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
2021MiMedx Lifts Adjusted Net Sales Outlook for FY21
MT
2021MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
AQ
2021Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunitie..
CI
2021MIMEDX Announces Speakers for December 7 Investor Day
AQ
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 255 M - -
Net income 2021 -19,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -26,6x
Yield 2021 -
Capitalization 502 M 502 M -
Capi. / Sales 2021 1,97x
Capi. / Sales 2022 1,88x
Nbr of Employees 735
Free-Float 96,6%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,52 $
Average target price 14,17 $
Spread / Average Target 213%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-25.17%502
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
MODERNA, INC.-38.99%62 828
VERTEX PHARMACEUTICALS3.18%57 608
LONZA GROUP AG-20.54%48 784